The American Heart Association holds something no rival can buy: a century of verified expertise, an active research program, and no product to sell. That last part is the advantage. The voices now answering heart-health questions in consumer feeds are paid in reactions or in attention; the institution is paid in neither, and that is why its answer carries more weight.
Consumer relevance is slipping anyway, because the process that settles an answer was never built to reach where people look. The institution waits until evidence is definitive and centrally approved, then publishes. The same question gets answered that day by an influencer or a chatbot, and the verified answer arrives years later to an audience that has already moved on.
Answering on time needs no new research. The expertise exists, the studies are running, the verified content is already built and paid for. What is missing is someone allowed to answer before the guideline is final: a credentialed expert who reads current evidence and answers within days, under a stated confidence grade that rises as evidence accrues until it becomes the official guideline. How early to speak, and at what stated confidence, is a board decision.
The questions
10Ten candidates. Pick the ones to ask at the panel.
Awareness that heart disease is the leading cause of death among women fell across the decade health content grew most abundant. Influencers and chatbots answered those questions every day for ten years; what did this institution leave unsaid that they did not?
FactThe decline concentrated where the paid-to-be-loud voices dominate; women kept looking, and the verified answer stopped reaching them.
Every person on this board accepts a 75%-sure answer from their own cardiologist because of who is answering. What stops the institution from saying "75% sure, and here is why" under its own name?
FactGraded certainty is already standard practice among the board's own physicians; only the institutional brand for it is missing.
When the most trusted voice stays quiet on a live question, someone else answers it within hours. Where is the line between caution that protects credibility and silence that lets whoever speaks first supply the answer?
FactIn a feed that rewards volume, staying silent still has a consequence: someone else fills the gap, often with misinformation.
Where would a second, visibly graded voice protect trust, and what must it look like for a consumer to tell it apart from the official guideline at a glance?
FactThe two voices only work if they never blur; a graded statement is a guideline that is not yet final, and its confidence grade must be visible in the design itself.
The institution's competitors in the consumer's feed are now individual people. Which of our own experts should be on camera in that format before the next board meeting, and what has to be true for us to develop them rather than borrow someone else's?
FactAmplifying an outside voice ties the institution's credibility to errors it can neither correct nor retract; the people with credentials and camera fluency are already on the board.
AI tools are already sending coronary-calcium numbers from routine mammograms to women and their doctors, with no guidance on what they mean. If we ship an interim read by 2026-09-30, what confidence grade goes on it, whose name owns it, and on what schedule do we revise it?
FactThe clinical signal is live now; the guideline cannot arrive for years; grade, owner, and revision cadence are the three signable decisions.
The verified content already exists and is already paid for; what is missing is being present where people actually look: the wearable alert, the search result, the gym door, the clinic lobby. If we could staff only two of those through 2026-12-31, which two, and what existing spend pays for it?
FactDistribution is a packaging task; the choice is which places to reach first and what funds them.
This board prices quantified risk on everything else it governs. What is the right peer for misinformation exposure on that same basis, and is a daily reach in the tens of thousands higher or lower than that peer's threshold?
FactDaily misinformation exposure has never been priced beside the other risks the board governs, so the board has never seen it priced as a real risk, while staff face it every day.
The studies underway are the largest body of evidence the institution never publishes. Which active studies would this board license to speak for themselves, "here is what we are studying, here is why, here is where the evidence leans," years before a guideline could?
FactThe fact that the institution is studying something already tells the public it is worth worrying about; treating studies only as raw material for a future guideline wastes that while the question is still open.
The deferral we want from a consumer survives only if our answer arrives within days. What do we fund, and what do we stop doing, to fund a team that can answer within days inside the FY2026 budget, ending 2026-12-31?
FactAnswering within days needs staffing, budget, and reporting lines the board must approve now.